Results 11 to 20 of about 210,319 (212)

Median-based incremental cost-effectiveness ratios with censored data [PDF]

Journal of Biopharmaceutical Statistics, 2015
Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study ...
Bang, Heejung, Zhao, Hongwei
openaire   +4 more sources

Cost-utility analysis of total knee arthroplasty alone and in comparison with post-surgical rehabilitation and conservative treatment in the Republic of Kazakhstan

Cost Effectiveness and Resource Allocation, 2022
Background Despite ample international knowledge on cost-effectiveness of total knee arthroplasty (TKA), it has never been a subject of investigation in Kazakhstan or other post-Soviet economies.
Dinara Serikova-Esengeldina, Natalya Glushkova, Gulzada Abdushukurova, Akmaral Mussakhanova, Ainur Mukhamejanova, Zaituna Khismetova, Dmitry Bokov, Alexandr Ivankov, Maiya Goremykina, Yuliya Semenova   +9 more
doaj   +1 more source

Nonparametric inference for time‐dependent incremental cost‐effectiveness ratios [PDF]

Statistics in Medicine, 2015
As the costs of medical care increase, more studies are evaluating cost in addition to effectiveness of treatments. Cost‐effectiveness analyses in randomized clinical trials have typically been conducted only at the end of follow‐up. However, cost‐effectiveness may change over time.
Laura M, Yee, Kwun Chuen, Gary Chan
openaire   +2 more sources

Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Olanzapine has been shown to have an additive effect on the three-drug antiemetic therapy consisting of aprepitant, palonosetron, and dexamethasone, in a highly emetogenic cisplatin-containing chemotherapy.
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi   +6 more
doaj   +1 more source

Opportunities for improving the efficiency of paediatric HIV treatment programmes [PDF]

, 2015
Objectives: To conduct two economic analyses addressing whether to: routinely monitor HIV-infected children on antiretroviral therapy (ART) clinically or with laboratory tests; continue or stop cotrimoxazole prophylaxis when children become stabilized on
Bakeera-Kitaka, S, Bwakura-Dangarembizi, M, Gibb, DM, Kekitinwa, A, Mabugu, T, Mugyenyi, P, Munderi, P, Musiime, V, Nahirya-Ntege, P, Nathoo, KJ, Revill, PA, Sculpher, MJ, Walker, AS, Walker, S   +13 more
core   +1 more source

Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. [PDF]

, 2008
OBJECTIVE: To compare the cost-effectiveness of eflornithine and melarsoprol in the treatment of human African trypanosomiasis. METHOD: We used data from a Médecins Sans Frontières treatment project in Caxito, Angola to do a formal cost-effectiveness ...
Adam, Blum, Burri, Burri, Chappuis, Commission for Macroeconomics and Health, Edejer, Evans, Goldie, Legros, Louis, Lutumba, Matovu, Murray, Murray, Pepin, Pepin, Pepin, Politi, Priotto, Robays, Schmid, Schmid, Stanghellini   +23 more
core   +2 more sources

Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods [PDF]

, 2002
Cost-effectiveness analysis is now an integral part of health technology assessment and addresses the question of whether a new treatment or other health care program offers good value for money.
A H Briggs, B J O’Brien, Department of Health and Aging Commonwealth of Australia, Fieller EC., Gold MR, Ontario Ministry of Health, Pratt JW, Stinnett AA   +7 more
core   +1 more source

Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. [PDF]

, 2011
BACKGROUND: Evidence on economically efficient strategies to lower blood pressure (BP) from low- and middle-income countries remains scarce. The Control of Blood Pressure and Risk Attenuation (COBRA) trial randomized 1341 hypertensive subjects in 12 ...
Bux, Rasool, Chaturvedi, Nish, Cosgrove, Peter, Ebrahim, Shah, Hatcher, Juanita, Hypertension Research Group, Islam, Muhammad, Jafar, Tazeen H, Poulter, Neil   +8 more
core   +2 more sources

Method for adjusting results of pharmacoeconomic studies from country to country using Bayesian statistics [PDF]

Hospital Pharmacology, 2021
Introduction: Key problems when transferring results of pharmacoeconomic studies between countries are: relative infrequency of observational design, utilization of unreliable estimates of input parameters in many of modelling studies, not reporting ...
Janković Slobodan M., Kostić Marina J., Milovanović Jasmina R.   +2 more
doaj   +1 more source

The death of cost-minimization analysis? [PDF]

, 2001
Four different types of evaluation methods, cost-benefit analysis (CBA), cost-utility analysis (CUA), cost-effectiveness analysis (CEA) and cost-minimization analysis (CMA), are usually distinguished. In this note, we pronounce the (near) death of CMA by
Altman, Briggs, Connolly, Connolly, Donaldson, Drummond, Drummond, Freiman, Gold, Kuck, Laska, O'Brien, O'Brien, Robinson, Robinson, Robinson, Robinson, Senn, Stinnett, Stinnett, Tambour, van Hout   +21 more
core   +2 more sources